Terri Sindelar Headquarters, Washington, D.C. May 19, 1994 (Phone: 202/358-1977) NOTE TO EDITORS: N94-37 NASA AND MULTIPLE SCLEROSIS ASSOCIATION TO COLLABORATE On Monday, May 23, at 9:30 a.m. EDT, NASA Administrator Daniel S. Goldin and the President of the Multiple Sclerosis Association of America (MSAA), John Hodson Sr., will sign an agreement to work cooperatively to advance the state of the art and application of cool suit technology for MS patients. The event, demonstrations and tour will take place at the National Rehabilitation Hospital (NRH), 102 Irving St., N.W., Washington, D.C. Madlyn Rhue, actress, artist, native Washingtonian and MS patient, will demonstrate how NASA's cool suit technology, derived from the Apollo mission space suit, relieved her symptoms and improved her quality of life. Jonathan M. Silver, Assistant Deputy Secretary of Commerce, and the White House coordinator for the President's new initiative to seek liaisons between the federal government and non-profit charities and foundations, will attend the event. A donation of $10,000 will be presented to MSAA by Mr. William Schnirring, President of Technology Utilization Foundation. The gift is to be used to place cool suits with financially challenged MS patients. At 10:30 a.m., Edward A. Eckenhoff, President and CEO of NRH, will lead a tour of the hospital's facilities where doctors conduct research on cool suit technology and other advanced technologies to help MS patients relieve disabling symptoms. MS patients undergoing treatment at NRH using the cool suit will discuss and evaluate their perceived improvement in walking, transfers, overall sense of well-being, and duration of the benefits of the cooling suit. May is MSAA awareness month. More than 300,000 Americans are afflicted with this progressively disabling neurological disease that has no known cause, cure or prevention. The disease attacks the myelin, or insulation, of nerve cell fibers. The cool suit lowers the body temperature and some patients report that the suit helps alleviate symptoms of slurred speech, impaired vision, weakness and unsteady gait, unusual fatigue and improves cognitive abilities. -end-